Investors

Filament Health is a leading exclusively natural psychedelic drug development company.

We are building a powerful platform to support the treatment of mental health conditions through FDA-approved psychedelic extracts from lab grown and regeneratively harvested plants.

Sign up for updates
symbol
securityname
$
closeprice
lastupdatedate
lastupdatetime

FH (NEO)

Recent News
22 June 2022
The Next Steps in Psychedelic Health Treatment
The Emerald Magazine
17 June 2022
Pharma-delics? UCSF Kicks Off First-Ever Trial of Drug Naturally Derived From Magic Mushrooms
San Francisco Standard
02 May 2022
Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward
Benzinga
30 April 2022
TDR’s Top 5 Psychedelic Developments For The Week Of April 25
The Dales Report
27 April 2022
Filament Health Keeps Adding Patents To Its Portfolio, Just Received Its Fourth
Benzinga
19 April 2022
News You Might Have Missed: April 19th, 2022
Microdose Buzz
Press Releases
August Virtual Investor Event
A virtual update with our senior management team on Thursday, August 12th offered insight into Filament’s business activities, clinical trials, and psychedelic drug development facility.
Corporate Presentation

Corporate Presentation

Financials

Privacy Policy

Anti-Bribery and Anti-Corruption Policy

Anti-Money Laundering and Anti-Terrorist Financing Policy

Majority Voting Policy

Insider Trading Policy

Diversity of Executive Officers Policy

Board of Directors Charter

Diversity of Board Policy

Code of Business Conduct and Ethics Policy

Whistleblower Policy

Charter of Nominating and Governance Committee

Charter of the Compensation Committee

Audit Committee Charter

Sedar Profile